{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T13:41:44Z","timestamp":1770817304541,"version":"3.50.1"},"reference-count":121,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","pathologyjournal.rcpa.edu.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.pathol.2025.10.005","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T17:29:32Z","timestamp":1763659772000},"page":"220-229","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Anaemia and bone disease"],"prefix":"10.1016","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1224-6908","authenticated-orcid":false,"given":"Karen","family":"Van","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasna","family":"Aleksova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phillip","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2748-5955","authenticated-orcid":false,"given":"John","family":"Kanellis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter R.","family":"Ebeling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9940-4376","authenticated-orcid":false,"given":"Frances","family":"Milat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pathol.2025.10.005_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1393865","article-title":"Prevalence and risk factors predisposing low bone mineral density in patients with thalassemia","volume":"15","author":"Ananvutisombat","year":"2024","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.pathol.2025.10.005_bib2","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-43633-6","article-title":"Association of osteoporosis and sarcopenia with fracture risk in transfusion-dependent thalassemia","volume":"13","author":"Thavonlun","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.pathol.2025.10.005_bib3","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1359\/jbmr.080505","article-title":"Bone disease in thalassemia: a frequent and still unresolved problem","volume":"24","author":"Vogiatzi","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.pathol.2025.10.005_bib4","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1182\/blood.V96.10.3624","article-title":"The importance of erythroid expansion in determining the extent of apoptosis in erythroid precursors in patients with beta-thalassemia major","volume":"96","author":"Centis","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2025.10.005_bib5","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0950-3536(98)80072-3","article-title":"Pathophysiology of thalassaemia","volume":"11","author":"Weatherall","year":"1998","journal-title":"Bailli\u00e8re\u2019s Clin Haematol"},{"key":"10.1016\/j.pathol.2025.10.005_bib6","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1365-2265.2008.03191.x","article-title":"Bone demineralization in adult thalassaemic patients: contribution of GH and IGF-I at different skeletal sites","volume":"69","author":"Scacchi","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.pathol.2025.10.005_bib7","doi-asserted-by":"crossref","DOI":"10.1093\/jbmrpl\/ziae117","article-title":"Bone turnover, areal BMD, and bone microarchitecture by second-generation high-resolution peripheral quantitative computed tomography in transfusion-dependent thalassemia","volume":"8","author":"Das","year":"2024","journal-title":"JBMR Plus"},{"key":"10.1016\/j.pathol.2025.10.005_bib8","doi-asserted-by":"crossref","first-page":"3966","DOI":"10.1210\/jc.2002-021548","article-title":"Bone histomorphometry in children and adolescents with beta-thalassemia disease: iron-associated focal osteomalacia","volume":"88","author":"Mahachoklertwattana","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pathol.2025.10.005_bib9","doi-asserted-by":"crossref","first-page":"110","DOI":"10.4274\/jcrpe.galenos.2018.2018.0074","article-title":"Pathogenesis of thalassemia major-associated osteoporosis: a review with insights from clinical experience","volume":"11","author":"Gaudio","year":"2019","journal-title":"J Clin Res Pediatr Endocrinol"},{"key":"10.1016\/j.pathol.2025.10.005_bib10","doi-asserted-by":"crossref","first-page":"3966","DOI":"10.1210\/jc.2002-021548","article-title":"Bone histomorphometry in children and adolescents with beta-thalassemia disease: iron-associated focal osteomalacia","volume":"88","author":"Mahachoklertwattana","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pathol.2025.10.005_bib11","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.crad.2005.07.006","article-title":"The radiological appearances of thalassaemia","volume":"61","author":"Tyler","year":"2006","journal-title":"Clin Radiol"},{"key":"10.1016\/j.pathol.2025.10.005_bib12","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1056\/NEJM199202273260904","article-title":"Osteopenia in men with a history of delayed puberty","volume":"326","author":"Finkelstein","year":"1992","journal-title":"NEJM"},{"key":"10.1016\/j.pathol.2025.10.005_bib13","first-page":"135","article-title":"Bone mineral density in normal children and young adults","volume":"34","author":"Rubin","year":"1993","journal-title":"Pediatr Res"},{"key":"10.1016\/j.pathol.2025.10.005_bib14","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/088800101300002937","article-title":"Evaluation of osteoporosis in thalassemia by quantitative computed tomography: is it reliable?","volume":"18","author":"Akpek","year":"2001","journal-title":"Pediatr Hematol Oncol"},{"key":"10.1016\/j.pathol.2025.10.005_bib15","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.bone.2011.03.765","article-title":"Characterization of low bone mass in young patients with thalassemia by DXA, pQCT and markers of bone turnover","volume":"48","author":"Fung","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.pathol.2025.10.005_bib16","doi-asserted-by":"crossref","first-page":"334","DOI":"10.14310\/horm.2002.1111030","article-title":"Normal lumbar bone mineral density in optimally treated children and young adolescents with beta-thalassemia major","volume":"6","author":"Christoforidis","year":"2007","journal-title":"Hormones (Athens)"},{"key":"10.1016\/j.pathol.2025.10.005_bib17","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJM199502023320506","article-title":"Bone marrow, cytokines, and bone remodeling \u2014 emerging insights into the pathophysiology of osteoporosis","volume":"332","author":"Manolagas","year":"1995","journal-title":"NEJM"},{"key":"10.1016\/j.pathol.2025.10.005_bib18","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1002\/jbmr.2266","article-title":"Thalassemia bone disease: a 19-year longitudinal analysis","volume":"29","author":"Wong","year":"2014","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.pathol.2025.10.005_bib19","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1186\/s13104-018-3616-y","article-title":"Dysregulation of the RANKL\/RANK\/OPG axis in thalassemia intermedia patients","volume":"11","author":"Alfaqih","year":"2018","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.pathol.2025.10.005_bib20","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1007\/s00277-010-1007-0","article-title":"Endocrine and bone disease in appropriately treated adult patients with beta-thalassemia major","volume":"89","author":"Baldini","year":"2010","journal-title":"Ann Hematol"},{"key":"10.1016\/j.pathol.2025.10.005_bib21","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s40618-024-02503-2","article-title":"Aetiology, diagnosis and treatment of thalassemia-associated osteoporosis of the adult","volume":"48","author":"Ambrosio","year":"2025","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.pathol.2025.10.005_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.jocd.2025.101565","article-title":"Bone quality is associated with fragility fracture in patients with hemoglobinopathies","volume":"28","author":"Fung","year":"2025","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.pathol.2025.10.005_bib23","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1365-2141.2010.08477.x","article-title":"Renal dysfunction in patients with thalassaemia","volume":"153","author":"Quinn","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pathol.2025.10.005_bib24","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1182\/bloodadvances.2018023085","article-title":"Denosumab in transfusion-dependent thalassemia osteoporosis: a randomized, placebo-controlled, double- phase 2b clinical trial","volume":"2","author":"Voskaridou","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.pathol.2025.10.005_bib25","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1182\/blood.V120.21.2121.2121","article-title":"Effects of anti rank ligand denusomab on beta thalassmia major induced osteoporosis","volume":"120","author":"Yassin","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2025.10.005_bib26","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s00223-022-00963-3","article-title":"Efficacy and safety of teriparatide in beta-thalassemia major associated osteoporosis: a real-life experience","volume":"111","author":"Gagliardi","year":"2022","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.pathol.2025.10.005_bib27","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.hoc.2022.12.005","article-title":"Pathogenic mechanisms in thalassemia I: ineffective erythropoiesis and hypercoagulability","volume":"37","author":"Bou-Fakhredin","year":"2023","journal-title":"Hematol Oncol\u2216 Clin North Am"},{"key":"10.1016\/j.pathol.2025.10.005_bib28","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00198-023-06937-x","article-title":"The influence of iron on bone metabolism disorders","volume":"35","author":"Zhang","year":"2024","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.pathol.2025.10.005_bib29","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1056\/NEJMcibr1304338","article-title":"Treating iron overload","volume":"368","author":"Camaschella","year":"2013","journal-title":"NEJM"},{"key":"10.1016\/j.pathol.2025.10.005_bib30","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1182\/blood.2023022502","article-title":"Management of iron overload: lessons from transfusion-dependent hemoglobinopathies","volume":"145","author":"Coates","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2025.10.005_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21228771","article-title":"Management of iron overload in beta-thalassemia patients: clinical practice update based on case series","volume":"21","author":"Pinto","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.pathol.2025.10.005_bib32","first-page":"21","article-title":"Pathophysiology of iron overload","volume":"1054","author":"Hershko","year":"2005","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.pathol.2025.10.005_bib33","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1053\/j.seminhematol.2021.06.002","article-title":"Shaping the bone through iron and iron-related proteins","volume":"58","author":"Ledesma-Colunga","year":"2021","journal-title":"Semin Hematol"},{"key":"10.1016\/j.pathol.2025.10.005_bib34","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s12011-019-01867-4","article-title":"The effect of abnormal iron metabolism on osteoporosis","volume":"195","author":"Che","year":"2020","journal-title":"Biol Trace Elem Res"},{"key":"10.1016\/j.pathol.2025.10.005_bib35","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.bone.2010.10.173","article-title":"Bone disease and skeletal complications in patients with beta thalassemia major","volume":"48","author":"Haidar","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.pathol.2025.10.005_bib36","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/ejh.13935","article-title":"Iron chelation therapy","volume":"110","author":"Bruzzese","year":"2023","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.pathol.2025.10.005_bib37","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1210\/er.2012-1026","article-title":"The osteocyte: an endocrine cell \u2026 and more","volume":"34","author":"Dallas","year":"2013","journal-title":"Endocr Rev"},{"key":"10.1016\/j.pathol.2025.10.005_bib38","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.bone.2008.03.003","article-title":"Fracture prevalence and relationship to endocrinopathy in iron overloaded patients with sickle cell disease and thalassemia","volume":"43","author":"Fung","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.pathol.2025.10.005_bib39","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1007\/s00198-016-3719-z","article-title":"Thalassemia-associated osteoporosis: a systematic review on treatment and brief overview of the disease","volume":"27","author":"Dede","year":"2016","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.pathol.2025.10.005_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111380","article-title":"Therapeutic potential of iron chelators on osteoporosis and their cellular mechanisms","volume":"137","author":"Zhang","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.pathol.2025.10.005_bib41","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(00)02357-6","article-title":"Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register","volume":"355","author":"Modell","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.pathol.2025.10.005_bib42","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(02)09740-4","article-title":"Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia","volume":"360","author":"Anderson","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.pathol.2025.10.005_bib43","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1006\/bcmd.2002.0510","article-title":"Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial","volume":"28","author":"Maggio","year":"2002","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.pathol.2025.10.005_bib44","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1182\/blood-2005-07-2948","article-title":"Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis","volume":"107","author":"Pennell","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2025.10.005_bib45","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.bcmd.2013.04.002","article-title":"Long-term treatment with deferiprone enhances left ventricular ejection function when compared to deferoxamine in patients with thalassemia major","volume":"51","author":"Filosa","year":"2013","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.pathol.2025.10.005_bib46","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3109\/03630269.2014.965781","article-title":"A systematic review and meta-analysis of deferiprone monotherapy and in combination with deferoxamine for reduction of iron overload in chronically transfused patients with \u03b2-thalassemia","volume":"38","author":"Kuo","year":"2014","journal-title":"Hemoglobin"},{"key":"10.1016\/j.pathol.2025.10.005_bib47","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00277-016-2633-y","article-title":"Longitudinal changes of endocrine and bone disease in adults with beta-thalassemia major receiving different iron chelators over 5 years","volume":"95","author":"Poggi","year":"2016","journal-title":"Ann Hematol"},{"key":"10.1016\/j.pathol.2025.10.005_bib48","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1002\/ajh.23844","article-title":"Endocrine function and bone disease during long-term chelation therapy with deferasirox in patients with beta-thalassemia major","volume":"89","author":"Casale","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.pathol.2025.10.005_bib49","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/s00247-002-0664-0","article-title":"Patterns of bone diseases in transfusion-dependent homozygous thalassaemia major: predominance of osteoporosis and desferri-oxamine-induced bone dysplasia","volume":"32","author":"Chan","year":"2002","journal-title":"Pediatr Radiol"},{"key":"10.1016\/j.pathol.2025.10.005_bib50","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00774-003-0449-z","article-title":"Bone mass and metabolism in thalassemic children and adolescents treated with different iron-chelating drugs","volume":"22","author":"Di Stefano","year":"2004","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.pathol.2025.10.005_bib51","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/j.1537-2995.2010.02939.x","article-title":"Fanconi syndrome in a patient with beta-thalassemia major after using deferasirox for 27 months","volume":"51","author":"Wei","year":"2011","journal-title":"Transfusion"},{"key":"10.1016\/j.pathol.2025.10.005_bib52","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1007\/s00198-012-2260-y","article-title":"Thalassemia bone disease: the association between nephrolithiasis, bone mineral density and fractures","volume":"24","author":"Wong","year":"2013","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.pathol.2025.10.005_bib53","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/jbmr.522","article-title":"A case of hypophosphatemic osteomalacia secondary to deferasirox therapy","volume":"27","author":"Milat","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.pathol.2025.10.005_bib54","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.bone.2016.01.011","article-title":"Deferasirox at therapeutic doses is associated with dose-dependent hypercalciuria","volume":"85","author":"Wong","year":"2016","journal-title":"Bone"},{"key":"10.1016\/j.pathol.2025.10.005_bib55","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1053\/crad.2000.0492","article-title":"Desferrioxamine-induced long bone changes in thalassaemic patients - radiographic features, prevalence and relations with growth","volume":"55","author":"Chan","year":"2000","journal-title":"Clin Radiol"},{"key":"10.1016\/j.pathol.2025.10.005_bib56","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1749-6632.2010.05542.x","article-title":"Treatment options for thalassemia patients with osteoporosis","volume":"1202","author":"Terpos","year":"2010","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.pathol.2025.10.005_bib57","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1093\/jn\/135.4.863","article-title":"Dietary iron positively influences bone mineral density in postmenopausal women on hormone replacement therapy","volume":"135","author":"Maurer","year":"2005","journal-title":"J Nutr"},{"key":"10.1016\/j.pathol.2025.10.005_bib58","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00394-013-0544-4","article-title":"Low iron status as a factor of increased bone resorption and effects of an iron and vitamin D-fortified skimmed milk on bone remodelling in young Spanish women","volume":"53","author":"Toxqui","year":"2014","journal-title":"Eur J Nutr"},{"key":"10.1016\/j.pathol.2025.10.005_bib59","doi-asserted-by":"crossref","first-page":"6891","DOI":"10.3390\/ijms24086891","article-title":"Iron deficiency and iron deficiency anemia: potential risk factors in bone loss","volume":"24","author":"Yang","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.pathol.2025.10.005_bib60","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.2147\/DDDT.S55499","article-title":"Optimizing iron delivery in the management of anemia: patient considerations and the role of ferric carboxymaltose","volume":"8","author":"Toblli","year":"2014","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.pathol.2025.10.005_bib61","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.bone.2009.06.017","article-title":"Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia","volume":"45","author":"Shimizu","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.pathol.2025.10.005_bib62","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1210\/jc.2008-2396","article-title":"FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study","volume":"94","author":"Schouten","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pathol.2025.10.005_bib63","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jama.2019.22450","article-title":"Effects of iron isomaltoside vs ferric carboxymaltose on hypophosphatemia in iron-deficiency anemia: two randomized clinical trials","volume":"323","author":"Wolf","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.pathol.2025.10.005_bib64","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41581-019-0189-5","article-title":"FGF23 at the crossroads of phosphate, iron economy and erythropoiesis","volume":"16","author":"Edmonston","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.pathol.2025.10.005_bib65","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s12916-020-01643-5","article-title":"Hypophosphatemia after high-dose iron repletion with ferric carboxymaltose and ferric derisomaltose-the randomized controlled HOMe aFers study","volume":"18","author":"Emrich","year":"2020","journal-title":"BMC Med"},{"key":"10.1016\/j.pathol.2025.10.005_bib66","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s00223-022-00987-9","article-title":"The measurement and interpretation of fibroblast growth factor 23 (FGF23) concentrations","volume":"112","author":"Heijboer","year":"2023","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.pathol.2025.10.005_bib67","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/cen.14832","article-title":"The effect of burosumab on intact and C-terminal FGF23 measurements","volume":"99","author":"Ashrafzadeh-Kian","year":"2023","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.pathol.2025.10.005_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2021.116202","article-title":"Hypophosphatemia after intravenous iron therapy: comprehensive review of clinical findings and recommendations for management","volume":"154","author":"Schaefer","year":"2022","journal-title":"Bone"},{"key":"10.1016\/j.pathol.2025.10.005_bib69","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1053\/j.jrn.2017.12.009","article-title":"Oral versus intravenous iron supplementation for the treatment of iron deficiency anemia in patients on maintenance hemodialysis\u2014effect on fibroblast growth factor-23 metabolism","volume":"28","author":"Fukao","year":"2018","journal-title":"J Ren Nutr"},{"key":"10.1016\/j.pathol.2025.10.005_bib70","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/ejcn.2016.217","article-title":"Parenteral iron polymaltose changes i:c-terminal FGF23 ratios in iron deficiency, but not in dialysis patients","volume":"71","author":"Tan","year":"2017","journal-title":"Eur J Clin Nutr"},{"key":"10.1016\/j.pathol.2025.10.005_bib71","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/ki.2012.176","article-title":"Update on fibroblast growth factor 23 in chronic kidney disease","volume":"82","author":"Wolf","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.pathol.2025.10.005_bib72","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.3390\/jcm9113587","article-title":"A pooled analysis of serum phosphate measurements and potential hypophosphataemia events in 45 interventional trials with ferric carboxymaltose","volume":"9","author":"Rosano","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.pathol.2025.10.005_bib73","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/apt.15386","article-title":"Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside","volume":"50","author":"Detlie","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.pathol.2025.10.005_bib74","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1007\/s12325-021-01770-2","article-title":"Intravenous iron-induced hypophosphatemia: an emerging syndrome","volume":"38","author":"Glaspy","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.pathol.2025.10.005_bib75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00005792-200001000-00001","article-title":"Severe hypophosphatemia. Pathophysiologic implications, clinical presentations, and treatment","volume":"79","author":"Subramanian","year":"2000","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.pathol.2025.10.005_bib76","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1002\/ehf2.14286","article-title":"Hypophosphataemia risk associated with ferric carboxymaltose in heart failure: a pooled analysis of clinical trials","volume":"10","author":"Rosano","year":"2023","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.pathol.2025.10.005_bib77","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/ajh.26100","article-title":"Parenteral iron therapy and phosphorus homeostasis: a review","volume":"96","author":"Kalantar-Zadeh","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.pathol.2025.10.005_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2024.117045","article-title":"Sustained hypophosphatemia after denosumab in a patient on hemodialysis","volume":"181","author":"Almodares","year":"2024","journal-title":"Bone"},{"key":"10.1016\/j.pathol.2025.10.005_bib79","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11154-024-09926-5","article-title":"No longer to be ignored: hypophosphatemia following intravenous iron administration","volume":"26","author":"Strubbe","year":"2025","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.pathol.2025.10.005_bib80","first-page":"781","article-title":"Severe hypocalcaemia following denosumab and iron infusion","volume":"27","author":"Cohen","year":"2022","journal-title":"Nephrol Ther"},{"key":"10.1016\/j.pathol.2025.10.005_bib81","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1111\/imj.16156","article-title":"Interaction between ferric carboxymaltose and denosumab causing severe hypocalcaemia and hypophosphataemia in a patient without chronic kidney disease","volume":"53","author":"Muhandiramge","year":"2023","journal-title":"Intern Med J"},{"key":"10.1016\/j.pathol.2025.10.005_bib82","article-title":"Concurrent denosumab and parenteral iron therapy precipitating severe hypocalcemia and hypophosphatemia","volume":"2","author":"Ye","year":"2024","journal-title":"JCEM Case Rep"},{"key":"10.1016\/j.pathol.2025.10.005_bib83","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s00198-019-05261-7","article-title":"Denosumab-induced hypocalcemia in patients with osteoporosis: can you know who will get low?","volume":"31","author":"Tsvetov","year":"2020","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.pathol.2025.10.005_bib84","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/imj.13001","article-title":"Severe hypocalcaemia and hypophosphataemia following intravenous iron and denosumab: a novel drug interaction","volume":"46","author":"Smyth","year":"2016","journal-title":"Intern Med J"},{"key":"10.1016\/j.pathol.2025.10.005_bib85","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1136\/gutjnl-2022-327897","article-title":"Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial","volume":"72","author":"Zoller","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.pathol.2025.10.005_bib86","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1007\/s11096-023-01548-2","article-title":"A systematic literature review and meta-analysis of the incidence of serious or severe hypersensitivity reactions after administration of ferric derisomaltose or ferric carboxymaltose","volume":"45","author":"Kennedy","year":"2023","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.pathol.2025.10.005_bib87","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1111\/imj.70100","article-title":"Intravenous administration of ferric derisomaltose is associated with a higher incidence of infusion reactions than ferric carboxymaltose, and unaffected by dilution volume","volume":"55","author":"Lucas","year":"2025","journal-title":"Intern Med J"},{"key":"10.1016\/j.pathol.2025.10.005_bib88","unstructured":"U.S. Food and Drug Administration. Injectafer (ferric carboxymaltose injection): prescribing information. Silver Spring (MD): U.S. Food and Drug Administration; approved 04\/2021. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/203565s009lbl.pdf (Accessed 5 June 2025)."},{"key":"10.1016\/j.pathol.2025.10.005_bib89","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1002\/jbmr.4558","article-title":"Osteomalacia as a complication of intravenous iron infusion: a systematic review of case reports","volume":"37","author":"Vilaca","year":"2022","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.pathol.2025.10.005_bib90","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1093\/rheumatology\/kez627","article-title":"Novel use of burosumab in refractory iron-induced FGF23-mediated hypophosphataemic osteomalacia","volume":"59","author":"Amarnani","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.pathol.2025.10.005_bib91","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/imj.70091","article-title":"Symptomatic hypocalcaemia after administration of denosumab and iron infusion in patients with normal and impaired renal function","volume":"55","author":"Pak","year":"2025","journal-title":"Intern Med J"},{"issue":"Issue Supplement 5","key":"10.1016\/j.pathol.2025.10.005_bib92","doi-asserted-by":"crossref","first-page":"v88","DOI":"10.1093\/jbmrpl\/ziae177","article-title":"\u201cDouble Trouble\u201d \u2013 the impact of iron infusion and antiresorptive therapy on calcium-phosphate homeostasis","author":"Stokes","year":"2025","journal-title":"JBMR Plus"},{"key":"10.1016\/j.pathol.2025.10.005_bib93","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2025-265474","article-title":"Delayed-onset hypocalcaemia and hypophosphataemia induced by iron infusion in the context of denosumab therapy","volume":"18","author":"Kadappu","year":"2025","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.pathol.2025.10.005_bib94","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1210\/clinem\/dgaa851","article-title":"Denosumab safety and efficacy among participants in the FREEDOM extension study with mild to moderate chronic kidney disease","volume":"106","author":"Broadwell","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pathol.2025.10.005_bib95","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000380960","article-title":"Hypocalcemia post denosumab in patients with chronic kidney disease stage 4-5","volume":"41","author":"Dave","year":"2015","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.pathol.2025.10.005_bib96","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2024-262595","article-title":"Severe hypophosphataemia and hypocalcaemia following intravenous ferric derisomaltose and denosumab administration","volume":"17","author":"Kritzinger","year":"2024","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.pathol.2025.10.005_bib97","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1210\/clinem\/dgae721","article-title":"Dose-specific effects of denosumab on serum calcium levels in patients with osteoporosis and various renal functions","volume":"110","author":"Sun","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pathol.2025.10.005_bib98","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1182\/blood-2004-06-2480","article-title":"Blood and bone: two tissues whose fates are intertwined to create the hematopoietic stem-cell niche","volume":"105","author":"Taichman","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2025.10.005_bib99","doi-asserted-by":"crossref","first-page":"e288","DOI":"10.1210\/clinem\/dgaa716","article-title":"Interactions of anemia, FGF-23, and bone in healthy adults-results from the study of health in pomerania (SHIP)","volume":"106","author":"Hannemann","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pathol.2025.10.005_bib100","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1111\/j.1532-5415.2010.03183.x","article-title":"The relationship between incidence of fractures and anemia in older multiethnic women","volume":"58","author":"Chen","year":"2010","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.pathol.2025.10.005_bib101","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1210\/jc.2017-00266","article-title":"Older men with anemia have increased fracture risk independent of bone mineral density","volume":"102","author":"Valderrabano","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pathol.2025.10.005_bib102","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11657-022-01130-9","article-title":"Anemia is associated with increased risk of non-vertebral osteoporotic fractures in elderly men: the MrOS Sweden cohort","volume":"17","author":"Kristjansdottir","year":"2022","journal-title":"Arch Osteoporos"},{"key":"10.1016\/j.pathol.2025.10.005_bib103","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1007\/s00198-009-1131-7","article-title":"Anemia and the risk of non-vertebral fractures: the Troms\u00f8 study","volume":"21","author":"J\u00f8rgensen","year":"2010","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.pathol.2025.10.005_bib104","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1359\/jbmr.070409","article-title":"Inflammatory markers and incident fracture risk in older men and women: the health aging and body composition study","volume":"22","author":"Cauley","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.pathol.2025.10.005_bib105","doi-asserted-by":"crossref","first-page":"M242","DOI":"10.1093\/gerona\/59.3.M242","article-title":"Inflammatory markers and physical performance in older persons: the InCHIANTI study","volume":"59","author":"Cesari","year":"2004","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.pathol.2025.10.005_bib106","doi-asserted-by":"crossref","first-page":"e1479","DOI":"10.1210\/clinem\/dgad399","article-title":"Hemoglobin levels improve fracture risk prediction in addition to FRAX clinical risk factors and bone mineral density","volume":"108","author":"Jaiswal","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pathol.2025.10.005_bib107","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s00198-004-1739-6","article-title":"Bone density and hemoglobin levels in older persons: results from the InCHIANTI study","volume":"16","author":"Cesari","year":"2005","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.pathol.2025.10.005_bib108","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1600-0609.2012.01819.x","article-title":"Renal aspects of thalassaemia a changing paradigm","volume":"89","author":"Bhandari","year":"2012","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.pathol.2025.10.005_bib109","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1365-2362.2005.01528.x","article-title":"Hyporesponsiveness to erythropoietic therapy due to chronic inflammation","volume":"35","author":"Macdougall","year":"2005","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.pathol.2025.10.005_bib110","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/MNH.0000000000000797","article-title":"Anemia and fibroblast growth factor 23 elevation in chronic kidney disease: homeostatic interactions and emerging therapeutics","volume":"31","author":"Agoro","year":"2022","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.pathol.2025.10.005_bib111","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1007\/s11914-014-0236-x","article-title":"Osteoblasts: a novel source of erythropoietin","volume":"12","author":"Wu","year":"2014","journal-title":"Curr Osteoporos Rep"},{"key":"10.1016\/j.pathol.2025.10.005_bib112","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/jcb.23347","article-title":"Erythropoietin mediated bone formation is regulated by mTOR signaling","volume":"113","author":"Kim","year":"2012","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.pathol.2025.10.005_bib113","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1179\/1607845415Y.0000000004","article-title":"Bone marrow iron distribution, hepcidin, and ferroportin expression in renal anemia","volume":"20","author":"B\u00e2rsan","year":"2015","journal-title":"Hematology"},{"key":"10.1016\/j.pathol.2025.10.005_bib114","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1093\/ndt\/gfy189","article-title":"Effects of erythropoietin on fibroblast growth factor 23 in mice and humans","volume":"34","author":"Hanudel","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.pathol.2025.10.005_bib115","first-page":"521","article-title":"Hyperparathyroidism and anemia in uremic subjects: a combined therapeutic approach","volume":"1","author":"Brancaccio","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pathol.2025.10.005_bib116","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252312838","article-title":"Anemia and mineral bone disorder in kidney disease patients: the role of FGF-23 and other related factors","volume":"25","author":"Carullo","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.pathol.2025.10.005_bib117","doi-asserted-by":"crossref","first-page":"99","DOI":"10.5414\/CN106640","article-title":"Improved parathyroid hormone control by cinacalcet is associated with reduction in darbepoetin requirement in patients with end-stage renal disease","volume":"76","author":"Battistella","year":"2011","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.pathol.2025.10.005_bib118","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/ndt\/gfr384","article-title":"Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism","volume":"27","author":"Koizumi","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.pathol.2025.10.005_bib119","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/jbmr.3026","article-title":"Bone health in patients with hematopoietic disorders of bone marrow origin: systematic review and meta- analysis","volume":"32","author":"Steer","year":"2017","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.pathol.2025.10.005_bib120","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s12020-019-02003-x","article-title":"Dual-energy X-ray absorptiometry pitfalls in thalassemia major","volume":"65","author":"Pellegrino","year":"2019","journal-title":"Endocrine"},{"key":"10.1016\/j.pathol.2025.10.005_bib121","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2020.115312","article-title":"The accurate relationship between spine bone density and bone marrow in humans","volume":"134","author":"Cheng","year":"2020","journal-title":"Bone"}],"container-title":["Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302525003411?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302525003411?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T17:49:59Z","timestamp":1770745799000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031302525003411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":121,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0031302525003411"],"URL":"https:\/\/doi.org\/10.1016\/j.pathol.2025.10.005","relation":{},"ISSN":["0031-3025"],"issn-type":[{"value":"0031-3025","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anaemia and bone disease","name":"articletitle","label":"Article Title"},{"value":"Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pathol.2025.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2025 Published by Elsevier B.V. on behalf of Royal College of Pathologists of Australasia. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}